2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2020
Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a ‘subclinical’ TTP state
Browning S, Bahar B, Lee AI, Gorshein E. Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a ‘subclinical’ TTP state. Hematology 2020, 25: 473-477. PMID: 33269995, DOI: 10.1080/16078454.2020.1848973.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraMicroangiopathic haemolytic anaemiaADAMTS13 activity levelsPlasma exchangeHaemolytic anaemiaThrombocytopenic purpuraHaematologic parametersSpontaneous recoveryAcute thrombotic thrombocytopenic purpuraMild haemolytic anaemiaUrgent plasma exchangeInitiation of therapyHereditary thrombotic thrombocytopenic purpuraActivity levelsDeficiency of ADAMTS13High mortality rateClinical remissionDisease remissionThrombotic microangiopathyPrompt treatmentThrombotic manifestationsADAMTS13 inhibitorUrgent therapyAsymptomatic femalesClinical manifestations
2017
Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation
Browning S, Quillen K, Sloan JM, Doros G, Sarosiek S, Sanchorawala V. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood 2017, 130: 1383-1386. PMID: 28698204, DOI: 10.1182/blood-2017-06-788729.Peer-Reviewed Original ResearchAdultAgedAged, 80 and overCohort StudiesCombined Modality TherapyDisease-Free SurvivalDose-Response Relationship, DrugFemaleHematopoietic Stem Cell TransplantationHumansImmunoglobulin Light ChainsImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedMolecular Targeted TherapyParaproteinsRecurrenceRetrospective StudiesSalvage Therapy